Bellerophon Therapeutics, Inc. (BLPH) financial statements (2020 and earlier)

Company profile

Business Address 184 LIBERTY CORNER ROAD, SUITE 302
WARREN, NJ 07059
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
12/31/2015
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments 1729146
Cash and cash equivalents 1729146
Restricted cash and investments 000 
Other undisclosed current assets 161223
Total current assets: 17362729
Noncurrent Assets
Property, plant and equipment 1112
Restricted cash and investments 0000
Other noncurrent assets  017
Total noncurrent assets: 1139
TOTAL ASSETS: 18373038
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities 4545
Accounts payable 3432
Accrued liabilities 1113
Due to related parties   00
Other undisclosed current liabilities 4233
Total current liabilities: 8768
Noncurrent Liabilities
Other undisclosed noncurrent liabilities 7325 
Total noncurrent liabilities: 7325 
Total liabilities: 1539128
Stockholders' equity
Stockholders' equity attributable to parent 4(3)1830
Common stock 1100
Additional paid in capital 180176142131
Accumulated other comprehensive loss  (0) (0)
Accumulated deficit (176)(179)(124)(101)
Total stockholders' equity: 4(3)1830
TOTAL LIABILITIES AND EQUITY: 18373038

Income statement (P&L) ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Gross profit:    2
Operating expenses (28)(25)(24)(48)
Operating loss: (28)(25)(24)(47)
Nonoperating income
(Investment Income, Nonoperating)
 0000
Interest and debt expense  (0)  
Loss from continuing operations before equity method investments, income taxes: (28)(25)(24)(46)
Other undisclosed income (loss) from continuing operations before income taxes 25(30)(1) 
Loss from continuing operations before income taxes: (3)(55)(24)(46)
Income tax benefit 5 0 
Net income (loss) available to common stockholders, diluted: 3(55)(24)(46)

Comprehensive Income ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Net income (loss): 3(55)(24)(46)
Other comprehensive income (loss) 0(0)0(0)
Comprehensive income (loss), net of tax, attributable to parent: 3(55)(24)(46)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: